Prognostic indicators of breakthrough hepatitis during lamivudine monotherapy for chronic hepatitis B virus infection

Journal of Gastroenterology

Volumn 39, Issue 8, 2004, Pages 769-775

  Tanaka, Yasuhito ^a   Yeo, Anthony E T ^b   Orito, Etsuro ^c   Ito, Kiyoaki ^d   Hirashima, Noboru ^d   Ide, Tatsuya ^e   Sata, Michio ^e   Mizokami, Masashi ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b Jacobus Pharmaceutical Co Inc   (United States)

^c NAGOYA CITY UNIVERSITY   (Japan)

^d CHUKYO HOSPITAL   (Japan)

^e KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breakthrough hepatitis; Hepatitis B virus; Lamivudine; Pre S deletion mutation; Precore mutation

Indexed keywords

ALANINE AMINOTRANSFERASE; GLYCYRRHIZIC ACID; INTERFERON; LAMIVUDINE; STRONGER NEOMINOPHAGEN; VIRUS DNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DNA DETERMINATION; FEMALE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; HAZARD ASSESSMENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SEQUENCE ANALYSIS; STATISTICAL SIGNIFICANCE; VIRUS CORE; VIRUS GENOME; VIRUS RESISTANCE; WILD TYPE;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CHROMOSOME DELETION; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; REGRESSION ANALYSIS;

EID: 4644345706     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-003-1387-1     Document Type: Article

References (17)

1. Lai CL, Chine RW, Leung NWY, Chang TT, Guan R, Tai DI, et al. A 1-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
2. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrell DLJ, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998;27:1670-7.
3. Mukaide M, Tanaka Y, Katayose S, Tano H, Murata M, Hikata M, et al. Development of real-time detection direct test for hepatitis B virus and comparison with two commercial tests using the WHO international standard. J Gastroenterol Hepatol 2003;18: 1264-71.
4. Sugauchi F, Mizokami M, Orito E, Ohno T, Kato H, Suzuki S, et al. A novel variant genotype C of hepatitis B virus identified in isolates from Australian Aborigines: complete genome sequence and phylogenetic relatedness. J Gen Virol 2001;82:883-92.
5. Minami M, Okanoue T, Nakajima E, Yasui K, Kagawa K, Kashima K. Significance of pre-S region-defective hepatitis B virus that emerged during exacerbation of chronic type B hepatitis. Hepatology 1993;17:558-63.
6. Fan YF, Lu CC, Chang YC, Chang TT, Lin PW, Lei HY, et al. Identification of a pre-S2 mutant in hepatocytes expressing a novel marginal pattern of surface antigen in advanced diseases of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2000;15:519-28.
7. Lu CC, Chen M, Ou JH, Yen TS. Key role of a CCAAT element in regulating hepatitis B virus surface protein expression. Virology 1995;206:1155-8.
8. Nakayoshi T, Maeshiro T, Nakayoshi T, Nakasone H, Sakugawa H, Kinjo F, et al. Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa Islands: a prospective study. J Med Virol 2003;70:350-4.
9. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001;33:218-23.
10. Sugauchi F, Ohno T, Orito E, Sakugawa H, Ichida T, Komatsu M, et al. Influence of hepatitis B virus genotypes on the development of preS-deletions and advanced liver diseases. J Med Virol 2003;70:537-44.
11. Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 2002;16:583-94.
12. Kajiya Y, Hamasaki K, Nakata K, Nakagawa Y, Miyazoe S, Takeda Y, et al. Full-length sequence and functional analysis of hepatitis B virus genome in a virus carrier: a case report suggesting the impact of pre-S and core promoter mutations on the progression of the disease. J Virol Hepatol 2002;9:149-56.
13. Fan YF, Lu CC, Chen WC, Yao WJ, Wang HC, Chang TT, et al. Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology 2001;33:277-86.
14. Melegari M, Scaglioni PP, Wands JR. The small envelope protein is required for secretion of a naturally occurring hepatitis B virus mutant with pre-S1 deleted. J Virol 1997;71:5449-54.
15. Xu Z, Yen TSB. Intracellular retention of surface protein by a hepatitis B virus mutant that release virion particles. J Virol 1996;70:133-40.
16. Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suzuki Y, Hosaka T, et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003;38:315-21.
17. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002;36:219-26.